ANIP ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc (ANIP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $383.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| CAREY STEPHEN P. | SVP & CFO | Sell 10b5-1 | 2,850 | $73.00 | $208.1K | 168,993 −1.7% of holding | |
| Lalwani Nikhil | PRESIDENT & CEO | Sell 10b5-1 | 5,400 | $71.00 | $383.4K | 339,089 −1.6% of holding | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell 10b5-1 | 500 | $70.79 | $35.4K | 73,924 −0.7% of holding | |
| Thoma Jeanne | Director | Sell 10b5-1 | 1,000 | $71.53 | $71.5K | 26,762 −3.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.